StocksReata Pharmaceuticals IncRETA

RETA

Reata Pharmaceuticals Inc

26.18 -1.08 (-3.96%)
Delayed Prices By NASDAQ, in USD Market Closed
Trade
S
26.13
B
26.26

Overview

Prev Close26.18
Day's Range25.76 - 27.25
52 Week Range25.00 - 153.12
Average Volume (3m)859.65K
1-Year Return-77.64%
Beta1.1084
Market Cap952.74M
P/E Ratio
Revenue13.75M
EPS-7.74
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Industry Pharmaceuticals Major
CEO J. Warren Huff
Employees 273

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2020: Reata Pharmaceuticals Inc's revenues decreased by 65.99% and amounted to 9.02M. Net income increased by 14.62% to -247.75M. Net assets decreased by 20.85% to 417.43M and EPS increased from -9.54 to -7.35.
RETA's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
N/A
Net Profit Margin
-1,022.69%
Operating Margin
-1,652.02%
Return On Investment
-35.43%
12/20
03/21
06/21
09/21
Total Revenue
3.19M
944K
2.22M
7.39M
Gross Profit
N/A
N/A
N/A
N/A
Operating Income
-53.98M
-54.91M
-60.13M
-58.1M
Net Income
-65.78M
-67.46M
-72.7M
-71.85M